Surʻat-e-Inzāl (Premature Ejaculation) is the most prevalent male sexual dysfunction affecting 25 - 40% global population of men. It is a universal disorder and is independent of age, social or marital status. It has a significant impact on both- patients and their partners, causing distress, anxiety and relationship difficulties affecting the quality of life. Several aetiologies have been proposed by various researchers which are not evidence-based but speculative. Accordingly the International Society for Sexual Medicine (ISSM) issued treatment guidelines for Premature Ejaculation (PE) recommending Serotonergic Antidepressants (SSRIs) and Local Anaesthetics (LA) for its management in modern medicine. However, these treatments were not actually developed for PE, and have limitations associated with their off-label use. Furthermore, nearly all the recommended drugs have a wider spectrum of adverse effects and serious drug interactions which sometimes could be fatal. On the other hand, centuries old Unani medicine offers a complete line of treatment for Surʻat-e-Inzāl based on traditional knowledge and experience. Unani physicians devised a large number of poly-herbal recipes which are still in vogue.  Majoon-e-Piyaz (MP) is one of the compound Unani formulations which are in use for the treatment of premature ejaculation since centuries. This article is an attempt to summarize scientific investigations in support of the claim made by Unani physicians regarding Majoon-e-Piyaz (MP).  Keywords: Surʻat-e-Inzāl, Premature Ejaculation, Majoon-e-Piyaz, Unani Medicine

Wajaul Mafasil (joint pain) is the most prevalent and common cause of morbidity and disability not only in India but also throughout the world. In spite of various scientific developments in conventional medicine, there is no specific therapy or cure available for joints pain particularly when the disease has progressed to chronic stage. Therefore, it is the need of the hour to explore new formulations from herbal sources which are safe and effective. The present trial was undertaken to scientifically validate the Unani pharmacopoeial compound formulations of Habb-e-Suranjan and Raughan-e-Suranjan for its safety and efficacy in patients with joints pain. Patients with joint pain, who gave written informed consent, were recruited in the study from general OPD of RRIUM, Chennai with the prior approval of the Institutional Ethics Committee. 97 patients completed the study treatment. The treatment protocol was followed for 14 days and the clinical evaluation was done on seventh and fourteenth day of the treatment. At the end of fourteenth day intensity of individual parameters like joints pain, swelling, tenderness and restriction of movement showed statistically significant improvement (p<0.05). Overall therapeutic response of the treatment observed in this study was 100%. It was observed that 47.4% cases were completely relieved; 51.4% cases were relieved while 1.2% cases showed partial relief after the treatment. The laboratory investigations showed that the drugs used in the study were safe as evident by its maintenance. It may be concluded that Habb-e-Suranjan in combination with Raughan-e-Suranjan possesses significant analgesic property and may be a better option for the patients of joint pain. Keywords: Arthritis, Joints pain, Wajaul Mafasil, Habb-e-Suranjan, Raughan-e-Suranjan

Objectives: The study aimed to establish the effectiveness of Unani add-on regimen by comparing theduration required for change in disease status from COVID-19 positive asymptomatic / mildto moderate symptomatic patients to asymptomatic negative. Methods: This single-centric, randomized, twin arm, controlled, clinical trial was carried out on a totalnumber of 62 RT-PCR confirmed COVID-19 patients. The Intervention group (IG) receivedUnani Regimen (Khameera Marwareed and Unani Joshanda) in addition to the conventional management, while the Control group (CG) received only conventional management. Results: It was observed that 16 (51.6%) patients in Intervention Group and 3 (9.4%) patients incontrol group became negative for COVID-19 at day 7 and remaining 13 out of 15 (93.5%) patients in Intervention Group and 20 out of 28 (74.1%) patients in control group becamenegative for COVID-19 at day 14 .This effect of the Unani Regimen in comparison to thecontrol group was statistically significant (p =0.003). Conclusions: It can be concluded that the change of COVID-19 positive asymptomatic / mild to moderate symptomatic patients to RT-PCR negative was much earlier in the add-on Unani regimen group as compared to control group. Bangladesh Journal of Medical Science Vol. 21 No. 04 October’22 Page : 901-911